Please note: the information on this page is provided for informational purposes only. As of 2011, Simmons Hanly Conroy is no longer accepting cases involving Ephedra or PPA.
Ephedra was officially known as a “natural” product, another way to describe a nutritional supplement. Because of this, it was not officially declared a “drug”, and therefore, it was not regulated by the Food and Drug Administration (FDA).
An active ingredient in Ephedra was Pheynlpropanolamine (PPA), which was also found in other medications such as cold remedies. Ephedra as well as PPA in other medications have caused serious side effects among users. Millions of people took the weight loss and performance-enhancing products that contained Ephedra.
On April 12, 2004, the FDA banned Ephedra. The products containing the Ephedra or PPA ingredient that were included in this ban are:
- Metabolife 356
- Xenadrine RFA-1
- Stacker 2
- Ripped Fuel
Health Complications and Ephedra & PPA Lawsuits
Side effects associated with Ephedra include:
- Heart Attack
- Hypertension (high blood pressure)
- Tachycardia (irregular heart rhythms)
PPA side effects include a high incidence of hemorrhagic or ischemic strokes, particularly in women.
The pharmaceutical lawyers at Simmons Hanly Conroy took on an early, active role in Ephedra lawsuits, recovering more than $15 million for their clients.* However since 2011, our firm is no longer accepting cases related to Ephedra or PPA.
Shareholder Paul Hanly served as a member of Plaintiffs’ Coordinating Committee in MDL 1598, In re Ephedra Products Liability Litigation. Shareholder Trent Miracle served on the Plaintiff’s Mediation Committee- In re Ephedra Products Liability Litigation.
* Please note that recovery results vary per client. The recovery amounts in each case reflect the specific facts of that case. Further, recovery amounts in past cases are not a guarantee of future results.
I am very pleased and had a wonderful experience with the firm. Would definitely use their services again.